Patents protect new inventions that are useful, novel, and involve an inventive step. In the field of agrochemicals, companies often try to patent combinations of existing active ingredients, claiming they work better together than separately. This case highlights the challenges in obtaining patent protection for such combinations when prior publications already describe similar mixtures. The court examined whether a specific insecticidal formulation using Fipronil and Emamectin Benzoate in a suspension concentrate (SC) form deserved a patent, or whether it was anticipated by existing knowledge in the public domain.
The judgment provides a clear example of how Indian courts apply the tests of novelty (newness) and inventive step (non-obviousness) under the Patents Act, 1970. It is particularly useful for understanding how prior art documents from other countries (here, Chinese patents) can block a patent grant in India if they disclose the same or very similar invention.
Factual Background
Crystal Crop Protection Limited filed Patent Application No. 1607/DEL/2010 on July 8, 2010, titled “Insecticidal Composition.” The invention claimed a broad-spectrum insecticide made by combining two active ingredients: Fipronil (a phenyl-pyrazole insecticide that disrupts the insect nervous system) at exactly 3.5% w/w and Emamectin Benzoate (an avermectin-class insecticide) at exactly 1.5% w/w, formulated as a suspension concentrate (SC).
The company argued that this specific combination and formulation offered a synergistic effect — meaning the two chemicals together killed insects more effectively than the sum of their individual effects. It claimed the product controlled both biting/chewing insects (like Spodoptera, fruit borers, Helicoverpa) and sucking insects (mites, leaf miners, thrips) in a single, cost-effective, and environment-friendly product. The appellant emphasized that no single prior product effectively handled such a wide range of pests without higher costs or environmental harm.
The complete specification highlighted lower dosage requirements, reduced residues, rain-fastness (not washing off easily), and better safety for non-target organisms. The independent Claim 1 specifically defined the composition with the exact percentages and SC form, while dependent claims covered adjuvants and their concentrations.
Procedural Background
After filing, the application underwent examination. The First Examination Report (FER) was issued in 2017, and the applicant responded and amended claims in 2019. Between 2017 and 2021, four pre-grant oppositions were filed by different parties, including Respondent No. 3 (represented by Advocate Ajay Amitabh Suman). The applicant replied to these oppositions.
A hearing was held before the Assistant Controller of Patents and Designs on November 23, 2021. On January 11, 2022, the Assistant Controller refused the application on three main grounds:
- Lack of novelty (the invention was not new);
- Lack of inventive step (it was obvious to a skilled person);
- Non-patentability under Section 3(d) of the Patents Act (mere new form of a known substance without enhanced efficacy).
The appellant filed an appeal under Section 117A of the Patents Act before the Delhi High Court, arguing that the Controller’s order lacked proper reasoning, failed to consider the synergistic effect, and misapplied the law on novelty and obviousness. The appellant relied on the Delhi High Court’s earlier decision in Biomoneta Research Pvt. Ltd. vs. Controller General of Patents (2023 SCC OnLine Del 1482) to support patentability of synergistic combinations.
Respondent No. 3 strongly defended the refusal, pointing out that multiple Chinese prior art documents already disclosed the same combination of Fipronil and Emamectin Benzoate in similar concentrations and formulations.
Reasoning
The court, through Justice Tushar Rao Gedela, carefully analyzed the invention and the cited prior arts. It first summarized the problem the invention sought to solve and the claimed solution, including the alleged synergy.
Lack of Novelty
The court found that the invention lacked novelty primarily because of two Chinese documents:
- CN1969627 (CN'627): Embodiment 5 explicitly disclosed a composition with exactly 3.5% Fipronil and 1.5% Emamectin Benzoate. Claim 8 described formulations as “suspending agent” (which corresponds to suspension concentrate/SC). The abstract and claims covered the same range of pests. The court noted that the specific percentages fell within the broad ranges disclosed, and the SC form was expressly taught.
- CN101019546 (CN'546): Example 5 again disclosed the identical 3.5% Fipronil + 1.5% Emamectin Benzoate combination, with co-toxicity coefficient showing synergy, and mentioned possible formulations including aqueous emulsions.
The court held that a single prior art document anticipating all essential features of the claim destroys novelty. Here, the exact active ingredients, their precise concentrations in one case, and the formulation type were already public knowledge. Minor differences in other components (like presence of synergists in some examples) did not save the claim, as the core combination was disclosed.
Lack of Inventive Step (Obviousness)
Even if not entirely anticipated, the court found the invention obvious to a person skilled in the art (PSA). It examined several additional documents:
- CN101066055A (CN'055) and CN101151970A (CN'970): These taught combinations of Fipronil and Emamectin Benzoate (or its derivatives) in overlapping ratios, with adjuvants, and various formulations including suspensions. They encouraged mixtures to reduce resistance and improve efficacy.
- CN1911037 (CN'037): Disclosed SC formulations of the same pair with ratios covering the claimed amounts, field trials showing good control, and synergy data.
- CN1579160 (CN'160): Explicitly taught synergistic pesticidal compositions of Fipronil and Emamectin Benzoate in suspension form, with examples and preparation methods.
The court explained that combining teachings from these documents (all in the same technical field of crop protection) would obviously lead a skilled formulator to the claimed specific percentages and SC form. SC formulations were a standard, well-known type in the industry for water-based, environment-friendly delivery. The alleged synergy was also demonstrated or suggested in prior arts.
The court rejected the argument of “teaching away” or improper mosaicing, noting that when documents disclose similar products in the same field, it reflects the state of the art rather than impermissible combining of unrelated teachings (Sterlite Technologies Ltd. v. HFCL Ltd., 2022 SCC OnLine Del 2895).
It also clarified the correct approach to inventive step, drawing from Agriboard International LLC vs. Deputy Controller of Patents (2022 SCC OnLine Del 940): the Controller must compare (i) the prior art, (ii) the claimed invention, and (iii) how a PSA would obviously bridge them. The impugned order satisfied this test.
Other Grounds
The court found it unnecessary to examine Section 3(d) (new form without enhanced efficacy) or sufficiency of disclosure once novelty and inventive step objections were upheld.
On the appellant’s procedural challenge (alleged non-application of mind or copy-pasting), the court held that mere similarity in reasoning with opposition submissions does not invalidate the order if independent analysis is evident. Here, the Controller had examined each prior art in detail.
Judgements with Complete Citation and Their Context Discussed
The court referred to and applied several key precedents to guide its analysis:
- Biomoneta Research Pvt. Ltd. vs. Controller General of Patents, Designs and Anr. (2023 SCC OnLine Del 1482): Cited by the appellant to argue that synergistic combinations of known ingredients can be patentable if they show unexpected enhancement. The court distinguished it on facts, as the prior arts here already suggested or demonstrated synergy for the same pair.
- Sterlite Technologies Ltd. v. HFCL Ltd. (2022 SCC OnLine Del 2895): Used to explain that using multiple documents disclosing similar products in the same field does not amount to impermissible “mosaicing.” It reflects the cumulative state of the art.
- Agriboard International LLC vs. Deputy Controller of Patents and Designs (2022 SCC OnLine Del 940): Provided the three-step framework for assessing inventive step — prior art disclosure, claimed invention, and obviousness to PSA. The court confirmed the Controller followed this structured approach.
These citations were discussed in the context of ensuring that patent refusals are reasoned, that obvious combinations in a crowded field like pesticides do not qualify for protection, and that synergy claims must be evaluated against existing disclosures.
Final Decision of the Court
The Delhi High Court upheld the Assistant Controller’s refusal order in its entirety. The appeal was dismissed without any order as to costs. The court concluded that the claimed composition lacked both novelty and inventive step, making it unpatentable under the Patents Act. It did not find any infirmity in the Controller’s reasoning warranting interference or remand for fresh consideration.
Point of Law Settled in the Case
A specific selection of known active ingredients in precise percentages and a standard formulation type (like SC) does not automatically qualify for a patent if prior publications already disclose the same combination, similar ratios, and the formulation option. Synergy, while potentially patentable in principle, must be genuinely unexpected and not suggested or shown in existing literature.
Controllers and courts must apply a structured analysis for inventive step, but when the field is well-developed and multiple documents point in the same direction, the invention is likely obvious. Mere procedural arguments about “copy-pasting” will not succeed if the final decision shows application of mind to the key issues.
The case underscores that patents are not granted for incremental or routine improvements in agrochemical formulations when the core idea is already in the public domain through foreign prior art.
Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested Titles for the Article:
- Delhi High Court Remands Insecticide Patent: Reasoned Order Required for Synergistic Fipronil-Emamectin Composition
- Synergistic Insecticidal Formulation Gets Second Chance: Key Takeaways from Crystal Crop Protection Patent Appeal
- Why the Delhi High Court Set Aside Refusal of Broad-Spectrum Pesticide Patent
- Patent Office Must Apply Mind Independently: Lessons from Crystal Crop’s Successful Appeal
